{"title":"Evaluation of Total White Blood Cells in Obese Subject in Khartoum State 2017","authors":"Ibrahim A Ali","doi":"10.23880/hij-16000148","DOIUrl":"https://doi.org/10.23880/hij-16000148","url":null,"abstract":"","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116934034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Chronic Lymphocytic Leukaemia (CLL) is a common haematological malignant neoplasm that is characterized by proliferation of clonal B-cell lymphocytes and infiltration of blood, lymph nodes, spleen and bone marrow. Autoimmune Hemolytic Anaemia (AIHA) is a medical condition in which patient’s red blood cells are being destructed by immune system through antibodies leading to red blood cell lysis. Venetoclax is a novel BCL-2 selective inhibitor introduced amongst patients with CLL refractory to standard treatment lines. Common adverse events in Venetoclax treatment are: neutropenia, thrombocytopenia and diarrhea. Case Report: The following case study presents 60-year-old female patient that developed an autoimmune hemolytic anemia after introducing Venetoclax for CLL diagnosed nearly 13 years before and treated with many other treatment lines. AIHA was resolved after withdrawing Venetoclax and being treated with steroids, Rituximab and plasmapheresis. After that, Venetoclax was reintroduced with carefully monitored hemolysis markers as well as maintaining steroids and Rituximab treatment with good results. Conclusion: Although AIHA caused by Venetoclax is still not mentioned by producer’s summary of product characteristic (sPC), it is valuable for clinicians to have the knowledge that such adverse event may occur (diagnosed after eliminating other causes) and how it can be handled based on experiences of fellow clinicians.
{"title":"Case Report of a 60-Year-Old Woman with Autoimmune Hemolytic Anaemia after Venetoclax","authors":"P. Vyas","doi":"10.23880/hij-16000216","DOIUrl":"https://doi.org/10.23880/hij-16000216","url":null,"abstract":"Background: Chronic Lymphocytic Leukaemia (CLL) is a common haematological malignant neoplasm that is characterized by proliferation of clonal B-cell lymphocytes and infiltration of blood, lymph nodes, spleen and bone marrow. Autoimmune Hemolytic Anaemia (AIHA) is a medical condition in which patient’s red blood cells are being destructed by immune system through antibodies leading to red blood cell lysis. Venetoclax is a novel BCL-2 selective inhibitor introduced amongst patients with CLL refractory to standard treatment lines. Common adverse events in Venetoclax treatment are: neutropenia, thrombocytopenia and diarrhea. Case Report: The following case study presents 60-year-old female patient that developed an autoimmune hemolytic anemia after introducing Venetoclax for CLL diagnosed nearly 13 years before and treated with many other treatment lines. AIHA was resolved after withdrawing Venetoclax and being treated with steroids, Rituximab and plasmapheresis. After that, Venetoclax was reintroduced with carefully monitored hemolysis markers as well as maintaining steroids and Rituximab treatment with good results. Conclusion: Although AIHA caused by Venetoclax is still not mentioned by producer’s summary of product characteristic (sPC), it is valuable for clinicians to have the knowledge that such adverse event may occur (diagnosed after eliminating other causes) and how it can be handled based on experiences of fellow clinicians.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132278563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Important complications of hemophilia are bleeding and joint deformity. Episodic treatment of hemophilia with Factor VIII arrests bleeding but not joint deformity. Thus there is a need to administer Factor VIII prophylactically to prevent bleeding and joint deformity. Apart from high dose prophylaxis practised in developing countries, low dose prophylaxis with 10-15 IU/ kg body weight twice/thrice a week is found to be quite effective in resource limited tropical country like India. Significant reduction in musculo-skeletal, visceral bleeding and joint deformity has been observed from various centres in India. Country wide awareness, including at district level, has happened now in India. Factor VIII is more freely supplied by Govt. agencies n o w.
{"title":"Low Dose Factor VIII Prophylaxis in Hemophilia: Indian Perspective","authors":"Dutta Tk","doi":"10.23880/hij-16000190","DOIUrl":"https://doi.org/10.23880/hij-16000190","url":null,"abstract":"Important complications of hemophilia are bleeding and joint deformity. Episodic treatment of hemophilia with Factor VIII arrests bleeding but not joint deformity. Thus there is a need to administer Factor VIII prophylactically to prevent bleeding and joint deformity. Apart from high dose prophylaxis practised in developing countries, low dose prophylaxis with 10-15 IU/ kg body weight twice/thrice a week is found to be quite effective in resource limited tropical country like India. Significant reduction in musculo-skeletal, visceral bleeding and joint deformity has been observed from various centres in India. Country wide awareness, including at district level, has happened now in India. Factor VIII is more freely supplied by Govt. agencies n o w.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130443945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Three EUA approved drug vaccine biologics have been approved for use by the United States Food and Drug Administration (FDA) for SARS-CoV-2. Their effect upon erythrocytes has not previously been reported. Methods: Seven individuals (4 men; 3 women) including two people with prior SARS-CoV-2 infections, one previously vaccinated with the Pfizer vaccine (two doses), and one previously vaccinated with the Moderna vaccine (three doses including one booster) provided blood drawn by venipuncture for analysis. In the first part of the study, one male subjected provided blood by venipuncture analysis. This blood was microscopically analyzed before and after the administration of the Pfizer BioNTech vaccine and normal saline. In the second part of the study, 3 men and 3 women provided blood samples obtained by venipuncture. Each of the individual’s blood was directly examined microscopically before and after administration of the Pfizer, Moderna, and Janssen vaccines to the blood. In the third part of the study the vaccines were independently analyzed for extraneous material. Results: Seven individuals including 4 men and 3 women showed normal erythrocyte coloration when their blood was drawn by venipuncture. Each individual’s blood when analyzed microscopically demonstrated normal morphology and appearance. In each instance, the administration of the Pfizer, Moderna, or Janssen vaccines directly into the blood on peripheral blood smear demonstrated an almost immediate loss of red color. This loss of red color persisted throughout the examination and was only seen where the vaccines mixed with erythrocytes. As the vaccines spread across the blood smear, the erythrocytes demonstrated (a) a loss of red color that was not transient, (b) clumping of erythrocytes not observed during the same time period following the administration of normal saline to the blood, and (c) alterations in the morphology of erythrocytes. While several of the vials had extraneous material; none of them had evidence of significant graphene oxide, living organisms, or nanotechnology. Conclusion: Administration of Pfizer, Moderna, and Janssen vaccines resulted in the immediate loss of red coloration present in erythrocytes. This loss of red coloration indicates that there is a disruption of the hemoglobin binding of oxygen. Since atmospheric oxygen is immediately available to re-saturate the hemoglobin molecules restoring the red color responsible for the function and name of erythrocytes; the results of this investigation suggest that there is an alteration in the hemoglobin molecule preventing the hemoglobin from binding with oxygen. This alteration of the hemoglobin molecule could be explained if the vaccines merge with the erythrocytes and release their genetic material (RNA or DNA) directly into the erythrocytes; having a prion altering effect upon the hemoglobin molecule. Some of the vaccine samples included extraneous materials. The vaccines did not include observab
{"title":"Pfizer, Moderna and Janssen vaccine InflammoThrombotic and Prion Type Effect on Erythrocytes When Added to Human Blood","authors":"R. Fleming","doi":"10.23880/hij-16000210","DOIUrl":"https://doi.org/10.23880/hij-16000210","url":null,"abstract":"Background: Three EUA approved drug vaccine biologics have been approved for use by the United States Food and Drug Administration (FDA) for SARS-CoV-2. Their effect upon erythrocytes has not previously been reported. Methods: Seven individuals (4 men; 3 women) including two people with prior SARS-CoV-2 infections, one previously vaccinated with the Pfizer vaccine (two doses), and one previously vaccinated with the Moderna vaccine (three doses including one booster) provided blood drawn by venipuncture for analysis. In the first part of the study, one male subjected provided blood by venipuncture analysis. This blood was microscopically analyzed before and after the administration of the Pfizer BioNTech vaccine and normal saline. In the second part of the study, 3 men and 3 women provided blood samples obtained by venipuncture. Each of the individual’s blood was directly examined microscopically before and after administration of the Pfizer, Moderna, and Janssen vaccines to the blood. In the third part of the study the vaccines were independently analyzed for extraneous material. Results: Seven individuals including 4 men and 3 women showed normal erythrocyte coloration when their blood was drawn by venipuncture. Each individual’s blood when analyzed microscopically demonstrated normal morphology and appearance. In each instance, the administration of the Pfizer, Moderna, or Janssen vaccines directly into the blood on peripheral blood smear demonstrated an almost immediate loss of red color. This loss of red color persisted throughout the examination and was only seen where the vaccines mixed with erythrocytes. As the vaccines spread across the blood smear, the erythrocytes demonstrated (a) a loss of red color that was not transient, (b) clumping of erythrocytes not observed during the same time period following the administration of normal saline to the blood, and (c) alterations in the morphology of erythrocytes. While several of the vials had extraneous material; none of them had evidence of significant graphene oxide, living organisms, or nanotechnology. Conclusion: Administration of Pfizer, Moderna, and Janssen vaccines resulted in the immediate loss of red coloration present in erythrocytes. This loss of red coloration indicates that there is a disruption of the hemoglobin binding of oxygen. Since atmospheric oxygen is immediately available to re-saturate the hemoglobin molecules restoring the red color responsible for the function and name of erythrocytes; the results of this investigation suggest that there is an alteration in the hemoglobin molecule preventing the hemoglobin from binding with oxygen. This alteration of the hemoglobin molecule could be explained if the vaccines merge with the erythrocytes and release their genetic material (RNA or DNA) directly into the erythrocytes; having a prion altering effect upon the hemoglobin molecule. Some of the vaccine samples included extraneous materials. The vaccines did not include observab","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130501315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The full blood count (FBC) or Complete Blood Count (CBC) is one of the most frequently requested haematological investigation performed in patients. It has the potential, when interpreted carefully and in relation to the clinical history can potentially yield very useful clinical information that assist in diagnosis and management of patients by clinicians. It usually comprises 13–19 parameters. The aim of this review was to highlight the evidenced based interpretation of full blood count parameters in health and disease. PubMed, Google Scholar, Science Direct and African Journals Online search was performed in January 2020 and studies on the components of a normal full blood count in health and several disease states was included in the review. Search keywords included full blood count and its clinically significance. FBC is a readily available test whose clinical utility is far reaching and can potentially monitor effect of drug treatment, pre-operative intervention and in the diagnosis of diseases such as anaemia, cancer, clotting issues, infection and immune system disorder. The parameters included in a normal FBC are sometimes under-utilized as most clinicians and nurses rely more on three of the components (HB, WBC and platelet count). FBC determination using either the 3 of 5-part differential haematology analyzer should be based on SOP using certified reagents, validated equipment and quality controlled (IQC and EQA) testing in a Good Laboratory Practice compliant laboratory. All clinically significant analyzer generated flags must be investigated. All results must be technically and clinically validated. Laboratories must identify findings and flags that should warrant the examination of a peripheral blood film as well as results that need to be communicated promptly to the requesting clinician to facilitate the need for immediate remedial action and effective management of patients. It is vital that result is not reviewed in isolation but holistically looking at trends over time and taking into consideration known diagnosis.
{"title":"Interpretation of Full Blood Count Parameters in Health and Disease","authors":"E. O.","doi":"10.23880/hij-16000180","DOIUrl":"https://doi.org/10.23880/hij-16000180","url":null,"abstract":"The full blood count (FBC) or Complete Blood Count (CBC) is one of the most frequently requested haematological investigation performed in patients. It has the potential, when interpreted carefully and in relation to the clinical history can potentially yield very useful clinical information that assist in diagnosis and management of patients by clinicians. It usually comprises 13–19 parameters. The aim of this review was to highlight the evidenced based interpretation of full blood count parameters in health and disease. PubMed, Google Scholar, Science Direct and African Journals Online search was performed in January 2020 and studies on the components of a normal full blood count in health and several disease states was included in the review. Search keywords included full blood count and its clinically significance. FBC is a readily available test whose clinical utility is far reaching and can potentially monitor effect of drug treatment, pre-operative intervention and in the diagnosis of diseases such as anaemia, cancer, clotting issues, infection and immune system disorder. The parameters included in a normal FBC are sometimes under-utilized as most clinicians and nurses rely more on three of the components (HB, WBC and platelet count). FBC determination using either the 3 of 5-part differential haematology analyzer should be based on SOP using certified reagents, validated equipment and quality controlled (IQC and EQA) testing in a Good Laboratory Practice compliant laboratory. All clinically significant analyzer generated flags must be investigated. All results must be technically and clinically validated. Laboratories must identify findings and flags that should warrant the examination of a peripheral blood film as well as results that need to be communicated promptly to the requesting clinician to facilitate the need for immediate remedial action and effective management of patients. It is vital that result is not reviewed in isolation but holistically looking at trends over time and taking into consideration known diagnosis.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"335 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134050389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood is one of the most important biological evidence found at a crime scene. In a violent crime , the blood sample obtained may belong to the victim, the suspect(murderer) or any other eyewitness. A proper analysis of blood samples obtained at a crime scene may contribute to clarify the circumstances under which the crime would have been committed. The information obtained by studying the blood sample may point the criminal investigation in the right direction and can help solve the crime. Hematology refers to the study of blood and it can play an important tool in analysing the crime. The blood analysis begins with the presumptive tests to confirm that a given sample is blood. Then precipitin technology may be used to find the species to which the blood belongs. Methods like DNA fingerprinting may be used to match the blood at crime scene with the blood of suspect to get a step closer to finding the criminal. We report here few of the analysis of blood that can be done to possibly fasten the process of case solving and find the right criminal.
{"title":"Hematology as an Analytical Tool in Forensic Science","authors":"G. K.","doi":"10.23880/hij-16000184","DOIUrl":"https://doi.org/10.23880/hij-16000184","url":null,"abstract":"Blood is one of the most important biological evidence found at a crime scene. In a violent crime , the blood sample obtained may belong to the victim, the suspect(murderer) or any other eyewitness. A proper analysis of blood samples obtained at a crime scene may contribute to clarify the circumstances under which the crime would have been committed. The information obtained by studying the blood sample may point the criminal investigation in the right direction and can help solve the crime. Hematology refers to the study of blood and it can play an important tool in analysing the crime. The blood analysis begins with the presumptive tests to confirm that a given sample is blood. Then precipitin technology may be used to find the species to which the blood belongs. Methods like DNA fingerprinting may be used to match the blood at crime scene with the blood of suspect to get a step closer to finding the criminal. We report here few of the analysis of blood that can be done to possibly fasten the process of case solving and find the right criminal.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"121 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130169669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bole is a popular delicacy in Port Harcourt, Nigeria. Bole is roast plantain, roasted above burning charcoal. It is usually roasted alongside yam, and fish. In the course of roasting Bole, women are exposed to smoke which in the long run may produce some effects on the blood. The study examines how the smoke inhaled by these women affects their packed cell volume, methaemoglobin and oxyhaemoglobin levels. This study was carried out on blood samples collected from women who roast Bole (test subjects), in Port Harcourt, specifically in Diobu and Borikiri area. Control subjects were apparently healthy women that were not exposed to smoke. A total of 40 samples (20 from test subjects and 20 from control subjects) were collected through standard vein-puncture technique. Packed cell volume was determined using microhaematocrit method, oxyhaemoglobin and methaemoglobin levels were analyzed using spectrophotometric method. Methaemoglobin level (4.94 ± 4.17%) and PCV level of the test subjects (39.45 ± 1.32%) were significantly greater than that of control subjects (methaemoglobin: 1.64 ± 0.39%) and (packed cell volume: 38.50 ± 1.40%); (p-value = 0.00114 and 0.032887 for methaemoglobin and PCV respectively). The Oxyhaemoglobin levels of test subjects (11.38 ± 1.29g/dl) was significantly lower than the oxyhaemoglobin level of the control subjects (15.39 ± 0.89g/dl); (p- value = 0.000). The study therefore reveals that exposure to smoke increases methemoglobin levels and decreases oxyhaemoglobin level; this does not support adequate physiological oxygen delivery to body tissues and organs and could lead to hypoxia. We therefore recommended that these women use other means which produces less smoke to roast their plantain (bole), increase hydration, and make use of nose masks to reduce smoke inhalation.
{"title":"Effect of Smoke Inhalation on Methaemoglobin, Oxyhaemoglobin and Packed Cell Volume of Plantain (“Bole”) Roasters in Port- Harcourt, Nigeria","authors":"Christian Sg","doi":"10.23880/hij-16000196","DOIUrl":"https://doi.org/10.23880/hij-16000196","url":null,"abstract":"Bole is a popular delicacy in Port Harcourt, Nigeria. Bole is roast plantain, roasted above burning charcoal. It is usually roasted alongside yam, and fish. In the course of roasting Bole, women are exposed to smoke which in the long run may produce some effects on the blood. The study examines how the smoke inhaled by these women affects their packed cell volume, methaemoglobin and oxyhaemoglobin levels. This study was carried out on blood samples collected from women who roast Bole (test subjects), in Port Harcourt, specifically in Diobu and Borikiri area. Control subjects were apparently healthy women that were not exposed to smoke. A total of 40 samples (20 from test subjects and 20 from control subjects) were collected through standard vein-puncture technique. Packed cell volume was determined using microhaematocrit method, oxyhaemoglobin and methaemoglobin levels were analyzed using spectrophotometric method. Methaemoglobin level (4.94 ± 4.17%) and PCV level of the test subjects (39.45 ± 1.32%) were significantly greater than that of control subjects (methaemoglobin: 1.64 ± 0.39%) and (packed cell volume: 38.50 ± 1.40%); (p-value = 0.00114 and 0.032887 for methaemoglobin and PCV respectively). The Oxyhaemoglobin levels of test subjects (11.38 ± 1.29g/dl) was significantly lower than the oxyhaemoglobin level of the control subjects (15.39 ± 0.89g/dl); (p- value = 0.000). The study therefore reveals that exposure to smoke increases methemoglobin levels and decreases oxyhaemoglobin level; this does not support adequate physiological oxygen delivery to body tissues and organs and could lead to hypoxia. We therefore recommended that these women use other means which produces less smoke to roast their plantain (bole), increase hydration, and make use of nose masks to reduce smoke inhalation.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"163 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125915343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Haemophilia is one of the predominant congenital coagulation disorder and a disease without ethnic or geographic limitations with incidence approximately 20 per 100 000 male births. Haemophilic patients are in regular need of blood and blood products and prone to risk of acquiring infections such as hepatitis B, C (HBV, HCV) and human immunodeficiency virus (HIV). Materials and methods: In this descriptive study, 98 haemophilic patients were selected for screening of HIV I and II, HBV, and HCV through the rapid immunochromatographic test method. Positive cases were confirmed by third generation enzyme linked immunosorbent assay (ELISA). Results: In this study, prevalence of hepatitis B among haemophilia patient was zero and prevalence of hepatitis C and HIV was 1.02% each. Conclusion: Prevalence of transfusion transmitted infections is much lower in this study than previous studies. The use of advanced methods, more sensitive tests, and virally inactivated factor concentrates might contribute to this reduction of viral infections in these patients.
{"title":"Transfusion Transmitted Infections in Patients with Haemophilia, a Study from Western Rajasthan, India","authors":"Gadepalli R","doi":"10.23880/hij-16000165","DOIUrl":"https://doi.org/10.23880/hij-16000165","url":null,"abstract":"Introduction: Haemophilia is one of the predominant congenital coagulation disorder and a disease without ethnic or geographic limitations with incidence approximately 20 per 100 000 male births. Haemophilic patients are in regular need of blood and blood products and prone to risk of acquiring infections such as hepatitis B, C (HBV, HCV) and human immunodeficiency virus (HIV). Materials and methods: In this descriptive study, 98 haemophilic patients were selected for screening of HIV I and II, HBV, and HCV through the rapid immunochromatographic test method. Positive cases were confirmed by third generation enzyme linked immunosorbent assay (ELISA). Results: In this study, prevalence of hepatitis B among haemophilia patient was zero and prevalence of hepatitis C and HIV was 1.02% each. Conclusion: Prevalence of transfusion transmitted infections is much lower in this study than previous studies. The use of advanced methods, more sensitive tests, and virally inactivated factor concentrates might contribute to this reduction of viral infections in these patients.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125326906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Mantle cell lymphoma is an aggressive B cell lymphoma with initially responded but easy to relapse and difficult to cure without survival plateau. The present recommendation of treatment includes induction chemo-immunotherapy followed by high dose chemotherapy plus autologous hematopoietic stem cell transplantation for transplant-eligible patients and chemo- immunotherapy followed by rituximab maintenance for transplant-ineligible patients. However, the best induction regimen remains to be defined and median five-year overall survival is around 60% on phase II trials of multi-center experiences. Materials & Methods: We investigated the real world outcome of our patients undergoing different regimens of induction chemo-immunotherapy and analyzed whether the intensity of treatment as one of prognostic factors upon the impact of survival. Results: Between 1997 and 2018, we analyzed 50 patients as the cohort with median age 62 (range 34 to 77), and male to female was 40 versus 10. Advanced stage of diseases were 86% (stage III 10% and stage IV 76%) of all patients. Ki-67 more than 30% of lymphomas were seen in 50% of patients and 34% with Ki-67 less than 30% and 16% were unknown. Thirty-four per cents of patients underwent intensive induction chemo-immunotherapy with or without ASCT and 66% received non- intensive treatment. Six of 31 relapsed patients had undergone allogeneic hematopoietic stem cell transplantation. Five-year overall survival was 52% with median OS 5.15 years. There was no significant survival difference between intensive versus non-intensive induction therapy with 53% versus 46% in first 5 years, however, better overall survival was seen in intensive therapy group when follow up longer. High Ki-67 patients had shorter 5-year overall survival (37% vs 63%). Transplant patients had better overall survival with 68% vs 47% in 5 years with median OS 10.86 vs 4.34 years. Conclusion: There was no statistically significant difference of survival during the initial five years but intensive induction chemo-immunotherapy with or without HDC/ASCT could achieve better survival in longer follow-up according to our real world experience.
目的:套细胞淋巴瘤是一种侵袭性B细胞淋巴瘤，初期有应答，但易复发，无生存平台，难以治愈。目前推荐的治疗方法包括:适合移植的患者，诱导化疗-免疫治疗后再进行大剂量化疗+自体造血干细胞移植;不适合移植的患者，化疗-免疫治疗后再进行美罗华维持。然而，最佳诱导方案仍有待确定，在多中心经验的II期试验中，中位5年总生存率约为60%。材料与方法:我们调查了接受不同诱导化疗-免疫治疗方案的患者的真实世界结果，并分析了治疗强度是否作为影响生存的预后因素之一。结果:在1997年至2018年期间，我们分析了50例患者作为队列，中位年龄为62岁(范围为34至77岁)，男女比例为40比10。晚期疾病占所有患者的86% (III期10%，IV期76%)。50%的患者中有超过30%的淋巴瘤Ki-67, 34%的患者Ki-67低于30%，16%的患者未知。34%的患者接受了有或没有ASCT的强化诱导化学免疫治疗，66%的患者接受了非强化治疗。31例复发患者中有6例接受了异基因造血干细胞移植。5年总生存率为52%，中位OS为5.15年。强化与非强化诱导治疗前5年的生存率无显著差异，分别为53%和46%，但随着随访时间的延长，强化治疗组的总生存率更高。高Ki-67患者的5年总生存率较短(37% vs 63%)。移植患者的5年总生存率为68% vs 47%，中位OS为10.86 vs 4.34年。结论:前5年生存率无统计学差异，但根据我们的实际经验，强化诱导化疗免疫治疗联合或不联合HDC/ASCT可在较长随访时间内获得更好的生存率。
{"title":"Long-Term Rather than Short-Term Survival Benefit in Mantle Cell Lymphoma Patients Treated With Intensive Chemo- Immunotherapy and Hematopoietic Stem Cell Transplantation in Real World Experience","authors":"Tan Td","doi":"10.23880/hij-16000172","DOIUrl":"https://doi.org/10.23880/hij-16000172","url":null,"abstract":"Purpose: Mantle cell lymphoma is an aggressive B cell lymphoma with initially responded but easy to relapse and difficult to cure without survival plateau. The present recommendation of treatment includes induction chemo-immunotherapy followed by high dose chemotherapy plus autologous hematopoietic stem cell transplantation for transplant-eligible patients and chemo- immunotherapy followed by rituximab maintenance for transplant-ineligible patients. However, the best induction regimen remains to be defined and median five-year overall survival is around 60% on phase II trials of multi-center experiences. Materials & Methods: We investigated the real world outcome of our patients undergoing different regimens of induction chemo-immunotherapy and analyzed whether the intensity of treatment as one of prognostic factors upon the impact of survival. Results: Between 1997 and 2018, we analyzed 50 patients as the cohort with median age 62 (range 34 to 77), and male to female was 40 versus 10. Advanced stage of diseases were 86% (stage III 10% and stage IV 76%) of all patients. Ki-67 more than 30% of lymphomas were seen in 50% of patients and 34% with Ki-67 less than 30% and 16% were unknown. Thirty-four per cents of patients underwent intensive induction chemo-immunotherapy with or without ASCT and 66% received non- intensive treatment. Six of 31 relapsed patients had undergone allogeneic hematopoietic stem cell transplantation. Five-year overall survival was 52% with median OS 5.15 years. There was no significant survival difference between intensive versus non-intensive induction therapy with 53% versus 46% in first 5 years, however, better overall survival was seen in intensive therapy group when follow up longer. High Ki-67 patients had shorter 5-year overall survival (37% vs 63%). Transplant patients had better overall survival with 68% vs 47% in 5 years with median OS 10.86 vs 4.34 years. Conclusion: There was no statistically significant difference of survival during the initial five years but intensive induction chemo-immunotherapy with or without HDC/ASCT could achieve better survival in longer follow-up according to our real world experience.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"204 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117347453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of Soluble Intercellular Adhesion Molecule-1 and Soluble P Selection in Sickle Cell Disease","authors":"Swem Ca","doi":"10.23880/hij-16000162","DOIUrl":"https://doi.org/10.23880/hij-16000162","url":null,"abstract":"","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126330864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：